Elanco Animal Health (NYSE:ELAN) Director Lawrence Erik Kurzius Acquires 10,000 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction dated Friday, December 12th. The shares were bought at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares in the company, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Elanco Animal Health Price Performance

Shares of ELAN traded up $0.79 during trading hours on Tuesday, reaching $22.49. The company had a trading volume of 6,024,643 shares, compared to its average volume of 5,861,403. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $23.70. The firm has a 50 day simple moving average of $21.75 and a 200-day simple moving average of $18.16. The company has a market capitalization of $11.17 billion, a price-to-earnings ratio of 374.81, a PEG ratio of 2.89 and a beta of 1.86.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the business posted $0.13 earnings per share. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research analyst reports. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their target price for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.78.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors have recently made changes to their positions in the stock. SJS Investment Consulting Inc. boosted its stake in shares of Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the last quarter. Huntington National Bank lifted its holdings in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after purchasing an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after buying an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp raised its position in shares of Elanco Animal Health by 3,018.3% in the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after buying an additional 2,807 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.